AU2015225954B2 - Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder - Google Patents
Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder Download PDFInfo
- Publication number
- AU2015225954B2 AU2015225954B2 AU2015225954A AU2015225954A AU2015225954B2 AU 2015225954 B2 AU2015225954 B2 AU 2015225954B2 AU 2015225954 A AU2015225954 A AU 2015225954A AU 2015225954 A AU2015225954 A AU 2015225954A AU 2015225954 B2 AU2015225954 B2 AU 2015225954B2
- Authority
- AU
- Australia
- Prior art keywords
- hydroxypyridazin
- ethyl
- hydroxy
- trifluoromethyl
- pyridazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1403944.0 | 2014-03-06 | ||
| GBGB1403944.0A GB201403944D0 (en) | 2014-03-06 | 2014-03-06 | New use |
| PCT/GB2015/050654 WO2015132608A1 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015225954A1 AU2015225954A1 (en) | 2016-07-07 |
| AU2015225954B2 true AU2015225954B2 (en) | 2020-06-18 |
Family
ID=50554599
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015225954A Ceased AU2015225954B2 (en) | 2014-03-06 | 2015-03-06 | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder |
Country Status (32)
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JO3115B1 (ar) | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
| GB201222711D0 (en) | 2012-12-17 | 2013-01-30 | Takeda Pharmaceutical | Novel compounds |
| US10118917B2 (en) | 2014-04-29 | 2018-11-06 | E I Du Pont De Nemours And Company | Pyridazinone herbicides |
| TWI785022B (zh) | 2017-03-28 | 2022-12-01 | 美商富曼西公司 | 新穎噠嗪酮類除草劑 |
| US11213030B2 (en) | 2017-06-30 | 2022-01-04 | Fmc Corporation | 4-(3,4-dihydronaphth-1-yl or 2H-chromen-4-yl)-5-hydroxy-2H-pyradizin-3-ones as herbicides |
| CN112569217B (zh) * | 2019-09-30 | 2022-04-22 | 厦门大学 | 戊酸衍生物在治疗遗传性小脑共济失调中的应用 |
| JP2021138648A (ja) | 2020-03-04 | 2021-09-16 | 武田薬品工業株式会社 | 経口固形製剤 |
| CA3209781A1 (en) | 2021-03-01 | 2022-09-09 | Takeda Pharmaceuticals Company Limited | Use of luvadaxistat for the treatment of cognitive impairment |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE321553T1 (de) * | 1998-06-10 | 2006-04-15 | Meiji Seika Kaisha | Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie |
| WO2003047558A2 (en) * | 2001-12-03 | 2003-06-12 | Genset S.A. | Treatment of cns disorders using d-amino acid oxidase and d-aspartate oxidase inhibitors |
| JO3115B1 (ar) * | 2011-08-22 | 2017-09-20 | Takeda Pharmaceuticals Co | مركبات بيريدازينون واستخدامها كمثبطات daao |
-
2014
- 2014-03-06 GB GBGB1403944.0A patent/GB201403944D0/en not_active Ceased
-
2015
- 2015-03-05 TW TW104106995A patent/TW201534591A/zh unknown
- 2015-03-06 US US15/123,796 patent/US20170014407A1/en not_active Abandoned
- 2015-03-06 GE GEAP201514284A patent/GEP20196984B/en unknown
- 2015-03-06 TR TR2018/09537T patent/TR201809537T4/tr unknown
- 2015-03-06 HR HRP20181082TT patent/HRP20181082T1/hr unknown
- 2015-03-06 MX MX2016010524A patent/MX2016010524A/es unknown
- 2015-03-06 WO PCT/GB2015/050654 patent/WO2015132608A1/en not_active Ceased
- 2015-03-06 DK DK15709324.6T patent/DK3113778T3/en active
- 2015-03-06 KR KR1020167027639A patent/KR20160126081A/ko not_active Withdrawn
- 2015-03-06 EA EA201691566A patent/EA036438B1/ru unknown
- 2015-03-06 MY MYPI2016703081A patent/MY202127A/en unknown
- 2015-03-06 SI SI201530291T patent/SI3113778T1/en unknown
- 2015-03-06 UA UAA201608758A patent/UA123352C2/uk unknown
- 2015-03-06 SG SG11201607106YA patent/SG11201607106YA/en unknown
- 2015-03-06 SM SM20180367T patent/SMT201800367T1/it unknown
- 2015-03-06 RS RS20180927A patent/RS57594B1/sr unknown
- 2015-03-06 MA MA39315A patent/MA39315A1/fr unknown
- 2015-03-06 ES ES15709324.6T patent/ES2676905T3/es active Active
- 2015-03-06 CN CN201580012352.1A patent/CN106102743A/zh active Pending
- 2015-03-06 LT LTEP15709324.6T patent/LT3113778T/lt unknown
- 2015-03-06 AU AU2015225954A patent/AU2015225954B2/en not_active Ceased
- 2015-03-06 EP EP15709324.6A patent/EP3113778B1/en active Active
- 2015-03-06 PL PL15709324T patent/PL3113778T3/pl unknown
- 2015-03-06 CA CA2940342A patent/CA2940342A1/en not_active Abandoned
- 2015-03-06 JP JP2016555645A patent/JP6510549B2/ja not_active Expired - Fee Related
- 2015-03-06 PT PT157093246T patent/PT3113778T/pt unknown
-
2016
- 2016-07-06 ZA ZA2016/04611A patent/ZA201604611B/en unknown
- 2016-08-23 IL IL247435A patent/IL247435A0/en active IP Right Grant
- 2016-08-25 CL CL2016002151A patent/CL2016002151A1/es unknown
- 2016-09-06 PH PH12016501751A patent/PH12016501751A1/en unknown
-
2018
- 2018-08-10 CY CY20181100843T patent/CY1120573T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2015225954B2 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| Carroll | Monoamine precursors in the treatment of depression | |
| JP5875191B2 (ja) | Ｃｍｔ及び関連障害を処置するための新たな組成物 | |
| JP5605659B2 (ja) | 細胞保護剤 | |
| AU782492B2 (en) | Method for the treatment of neurological or neuropsychiatric disorders | |
| EA023380B1 (ru) | Комбинация пилокарпина и метимазола для лечения заболевания шарко-мари-тута и связанных с ним нарушений | |
| JP2022553371A (ja) | α１Ａ－ＡＲ部分アゴニストを用いて神経障害を治療するための方法 | |
| WO2018200977A1 (en) | Pimavanserin for treating impulse control disorder | |
| EA017915B1 (ru) | Kcnq-открыватели калиевых каналов, применяемые для лечения или ослабления симптомов шизофрении | |
| Chen et al. | Intra-cerebellar infusion of NMDA receptor antagonist AP5 disrupts classical eyeblink conditioning in rabbits | |
| EA014576B1 (ru) | Комбинированные препараты, содержащие бифепрунокс и l-допу | |
| TW201211021A (en) | Methods of use of cyclic amide derivatives to treat schizophrenia | |
| Barr et al. | Repeated electroconvulsive shock attenuates the depressive-like effects of d-amphetamine withdrawal on brain reward function in rats | |
| TWI864376B (zh) | 焦慮症處置用組成物及處置方法 | |
| HK1230925A1 (en) | Pyridazine derivatives for use in the prevention or treatment of an ataxic disorder | |
| Júnior et al. | Effects of constant intravenous infusion of detomidine alone or combined with butorphanol or methadone for standing sedation in horses: A randomized clinical trial | |
| US20080318926A1 (en) | Methods of Treating Mood Disorders Using Pyridyloxymethyl and Benzisoxazole Azabicyclic Derivatives | |
| EP4203948A1 (en) | Compositions and uses thereof | |
| Vets et al. | SAGI DENENBERG | |
| CN107648235B (zh) | 普纳替尼在制备治疗缺血/再灌注损伤药物中的应用 | |
| Rizek et al. | Management of Advanced Parkinson’s Disease | |
| WO2022079307A1 (en) | Compositions and uses thereof | |
| CN117899219A (zh) | Htr1d作为靶点用于治疗疼痛-抑郁共病的药物中的应用 | |
| Cole | Highlights from the 14th International Congress of Parkinson´ s Disease and Movement Disorders: Future treatments | |
| Coffman | Role of the Serotonin 5HT 2c Receptor in Mediation of a Behavior that is a Potential Animal Model for OCD |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |